Table 5

Summary of studies reporting HER2 status in primary breast cancer and metastases
Author Patient numbers “Gain” in HER2 “Loss” of HER2
Giotta [8] 20 5% 5%
Gancberg [9]:
Immunohistochemistry 100 6% -
In situ hybridisation 68 4% 3%
Nikura [10] 182 - 24%
Amir [11] 83 8% (6/73) 20% (2/10)
Gong [12] 60 1.6% 1.6%
Tapia [13] 105 1.9% 0.9%
Fabi [14] 137 8.7% 1.5%
Simon [15] 122 2.2% 6.5%
Lindstrom [16] 76 6.5% 10.5%

Chan et al.

Chan et al. BMC Cancer 2012 12:555   doi:10.1186/1471-2407-12-555

Open Data